糖皮质激素而非TNF拮抗剂与炎症性肠病患者不良COVID-19结局相关:国际登记研究结果
基于SECURE-IBD国际登记中33个国家525例确诊COVID-19的IBD患者,7%发生重症COVID-19,3%死亡。多变量分析显示高龄、≥2种合并症、全身糖皮质激素及柳氮磺吡啶/5-氨基水杨酸使用与重症COVID-19相关,而TNF拮抗剂无此关联。
要点
- IBD患者中重症COVID-19占7%,病死率3%。
- 全身糖皮质激素使重症COVID-19风险显著升高(aOR 6.9)。
- TNF拮抗剂与重症COVID-19无显著关联(aOR 0.9)。
核心结论
- IBD患者中高龄、≥2种合并症及全身糖皮质激素使用与重症COVID-19相关,但无法确定因果关系。
- TNF拮抗剂治疗未显示与重症COVID-19相关。
研究设计与样本
- SECURE-IBD为大型国际登记研究,纳入33个国家525例确诊COVID-19的IBD患者(中位年龄43岁,53%为男性)。
- 计算年龄标化死亡率比,并采用多变量logistic回归分析重症COVID-19相关因素。
- 重症COVID-19定义为入住ICU、使用呼吸机和/或死亡。
主要发现
- IBD患者标化死亡率比相对中国、意大利、美国数据分别为1.8(95%CI 0.9-2.6)、1.5(95%CI 0.7-2.2)、1.7(95%CI 0.9-2.5)。
- 重症COVID-19危险因素包括年龄增加(aOR 1.04;95%CI 1.01-1.02)、≥2种合并症(aOR 2.9;95%CI 1.1-7.8)、全身糖皮质激素(aOR 6.9;95%CI 2.3-20.5)、柳氮磺吡啶或5-氨基水杨酸使用(aOR 3.1;95%CI 1.3-7.7)。
- TNF拮抗剂与重症COVID-19无关联(aOR 0.9;95%CI 0.4-2.2)。
关键数值与推荐
- 重症COVID-19定义为入住ICU、使用呼吸机和/或死亡。
- 全身糖皮质激素使用与重症COVID-19的aOR为6.9(95%CI 2.3-20.5)。
- TNF拮抗剂与重症COVID-19的aOR为0.9(95%CI 0.4-2.2)。
- ≥2种合并症的aOR为2.9(95%CI 1.1-7.8)。
- 柳氮磺吡啶或5-氨基水杨酸使用的aOR为3.1(95%CI 1.3-7.7)。
临床怎么用
- IBD患者感染COVID-19时,应评估高龄、合并症数量及全身糖皮质激素使用等重症风险因素。
- TNF拮抗剂治疗与重症COVID-19无关联,不应仅因COVID-19风险而常规停用。
- 使用全身糖皮质激素的IBD患者需加强COVID-19监测与防护。
局限性
- 无法确定观察到的关联为因果关系。
- 登记研究可能存在报告偏倚与混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown. We sought to characterize the clinical course of COVID-19 among patients with IBD and evaluate the association among demographics, clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes. METHODS: Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of patients with IBD with confirmed COVID-19. We calculated age-standardized mortality ratios and used multivariable logistic regression to identify factors associated with severe COVID-19, defined as intensive care unit admission, ventilator use, and/or death. RESULTS: 525 cases from 33 countries were reported (median age 43 years, 53% men). Thirty-seven patients (7%) had severe COVID-19, 161 (31%) were hospitalized, and 16 patients died (3% case fatality rate). Standardized mortality ratios for patients with IBD were 1.8 (95% confidence interval [CI], 0.9-2.6), 1.5 (95% CI, 0.7-2.2), and 1.7 (95% CI, 0.9-2.5) relative to data from China, Italy, and the United States, respectively. Risk factors for severe COVID-19 among patients with IBD included increasing age (adjusted odds ratio [aOR], 1.04; 95% CI, 1.01-1.02), ≥2 comorbidities (aOR, 2.9; 95% CI, 1.1-7.8), systemic corticosteroids (aOR, 6.9; 95% CI, 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (aOR, 3.1; 95% CI, 1.3-7.7). Tumor necrosis factor antagonist treatment was not associated with severe COVID-19 (aOR, 0.9; 95% CI, 0.4-2.2). CONCLUSIONS: Increasing age, comorbidities, and corticosteroids are associated with severe COVID-19 among patients with IBD, although a causal relationship cannot be definitively established. Notably, tumor necrosis factor antagonists do not appear to be associated with severe COVID-19.
引用
- Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020. PMID: 32425234. doi:10.1053/j.gastro.2020.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。